BRD4770

inhibits G9a histone methyltransferase; structure in first source

Networked: 4 relevant articles (0 outcomes, 1 trials/studies)

1.	Neoplasms (Cancer) 07/20/2012 - "BRD4770 may be a useful tool to study G9a and its role in senescence and cancer cell biology." 09/01/2023 - "BRD4770, an inhibitor of EHMT2/G9a, plays a critical role in several kinds of cancers. "
2.	Neointima 09/01/2023 - "BRD4770 inhibits vascular smooth muscle cell proliferation via SUV39H2, but not EHMT2 to protect against neointima formation."
3.	B-Cell Lymphoma (Lymphoma, B Cell) 06/27/2013 - "The combination of gossypol and BRD4770 increased LC3-II levels and the autophagosome number in PANC-1 cells, and the compound combination appears to act in a BNIP3 (B-cell lymphoma 2 19-kDa interacting protein)-dependent manner, suggesting that these compounds act together to induce autophagy-related cell death in pancreatic cancer cells. "
4.	Pancreatic Neoplasms (Pancreatic Cancer) 06/27/2013 - "The combination of gossypol and BRD4770 increased LC3-II levels and the autophagosome number in PANC-1 cells, and the compound combination appears to act in a BNIP3 (B-cell lymphoma 2 19-kDa interacting protein)-dependent manner, suggesting that these compounds act together to induce autophagy-related cell death in pancreatic cancer cells. "
5.	Inflammation (Inflammations) 01/01/2022 - "RNA-sequencing analysis revealed that there was a positive feedback regulation between ferroptosis and inflammatory response, and BRD4770 can reverse the effects of inflammation activation on ferroptosis. "